-
Brunetto MR, Oliveri F, Coco B, Leandro G, Colombatto P, Gorin JM, Bonino F, 2002: Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study[J]. J Hepatol, 36, 263-270.
-
Deres K, Schroder CH, Paessens A, Goldmann S, Hacker HJ, Weber O, Kramer T, Niewohner U, Pleiss U, Stoltefuss J, Graef E, Koletzki D, Masantschek RN, Reimann A, Jaeger R, Gross R, Beckermann B, Schlemmer KH, Haebich D, Rubsamen-Waigmann H, 2003: Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids[J]. Science, 299, 893-896. doi: 10.1126/science.1077215
-
EASL clinical practice guidelines , 2012: Management of chronic hepatitis B virus infection[J]. J Hepatol, 57, 167-185. doi: 10.1016/j.jhep.2012.02.010
-
Farkowski MM, Maciag A, Kowalik I, Konka M, Szwed H, Pytkowski M, 2019: Intravenous antazoline, a first-generation antihistaminic drug with antiarrhythmic properties, is a suitable agent for pharmacological cardioversion of atrial fibrillation induced during pulmonary vein isolation due to the lack of influence on atrio-venous conduction and high clinical effectiveness (AntaEP Study)[J]. Br J Clin Pharmacol, 85, 1552-1558. doi: 10.1111/bcp.13940
-
Hampel A, Solbach P, Cornberg M, Schmidt RE, Behrens GM, Jablonka A, 2016: Current seroprevalence, vaccination and predictive value of liver enzymes for hepatitis B among refugees in Germany[J]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 59, 578-583. doi: 10.1007/s00103-016-2333-8
-
Kwon H, Lok AS, 2011: Hepatitis B therapy[J]. Nat Rev Gastroenterol Hepatol, 8, 275-284. doi: 10.1038/nrgastro.2011.33
-
Ladner SK, Otto MJ, Barker CS, Zaifert K, Wang GH, Guo JT, Seeger C, King RW, 1997: Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication[J]. Antimicrob Agents Chemother, 41, 1715-1720. doi: 10.1128/AAC.41.8.1715
-
Lampertico P, Invernizzi F, Vigano M, Loglio A, Mangia G, Facchetti F, Primignani M, Jovani M, Iavarone M, Fraquelli M, Casazza G, de Franchis R, Colombo M, 2015: The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: a 12-year prospective cohort study[J]. J Hepatol, 63, 1118-1125. doi: 10.1016/j.jhep.2015.06.006
-
Lange CM, Bojunga J, Hofmann WP, Wunder K, Mihm U, Zeuzem S, Sarrazin C, 2009: Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function[J]. Hepatology, 50, 2001-2006. doi: 10.1002/hep.23346
-
Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, Heathcote EJ, Manns M, Bzowej N, Niu J, Han SH, Hwang SG, Cakaloglu Y, Tong MJ, Papatheodoridis G, Chen Y, Brown NA, Albanis E, Galil K, Naoumov NV, 2009: 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B[J]. Gastroenterology, 136, 486-495. doi: 10.1053/j.gastro.2008.10.026
-
Marcellin P, Chang TT, Lim SG, Sievert W, Tong M, Arterburn S, Borroto-Esoda K, Frederick D, Rousseau F, 2008: Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B[J]. Hepatology, 48, 750-758. doi: 10.1002/hep.22414
-
Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, Haussinger D, 1996: Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B[J]. N Engl J Med, 334, 1422-1427. doi: 10.1056/NEJM199605303342202
-
Ott JJ, Stevens GA, Groeger J, Wiersma ST, 2012: Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity[J]. Vaccine, 30, 2212-2219. doi: 10.1016/j.vaccine.2011.12.116
-
Papatheodoridis GV, Manesis E, Hadziyannis SJ, 2001: The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B[J]. J Hepatol, 34, 306-313. doi: 10.1016/S0168-8278(00)00094-5
-
Pei R, Qin B, Zhang X, Zhu W, Kemper T, Ma Z, Trippler M, Schlaak J, Chen X, Lu M, 2014: Interferon-induced proteins with tetratricopeptide repeats 1 and 2 are cellular factors that limit hepatitis B virus replication[J]. J Innate Immun, 6, 182-191. doi: 10.1159/000353220
-
Perrillo RP, Martin P, Lok AS, 2015: Preventing hepatitis B reactivation due to immunosuppressive drug treatments[J]. JAMA, 313, 1617-1618. doi: 10.1001/jama.2015.2571
-
Purdy JB, Gafni RI, Reynolds JC, Zeichner S, Hazra R, 2008: Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus[J]. J Pediatr, 152, 582-584. doi: 10.1016/j.jpeds.2007.12.020
-
Schulze A, Schieck A, Ni Y, Mier W, Urban S, 2010: Fine mapping of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction[J]. J Virol, 84, 1989-2000. doi: 10.1128/JVI.01902-09
-
Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ, 2015: Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013[J]. Lancet, 386, 1546-1555. doi: 10.1016/S0140-6736(15)61412-X
-
Seeger C, Mason WS, 2015: Molecular biology of hepatitis B virus infection[J]. Virology 479-, 480, 672-686.
-
Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, Abu-Raddad LJ, Assadi R, Bhala N, Cowie B, Forouzanfour MH, Groeger J, Hanafiah KM, Jacobsen KH, James SL, MacLachlan J, Malekzadeh R, Martin NK, Mokdad AA, Mokdad AH, Murray CJL, Plass D, Rana S, Rein DB, Richardus JH, Sanabria J, Saylan M, Shahraz S, So S, Vlassov VV, Weiderpass E, Wiersma ST, Younis M, Yu C, El Sayed ZM, Cooke GS, 2016: The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013[J]. Lancet, 388, 1081-1088. doi: 10.1016/S0140-6736(16)30579-7
-
Tong S, Revill P, 2016: Overview of hepatitis B viral replication and genetic variability[J]. J Hepatol, 64, S4-S16. doi: 10.1016/j.jhep.2016.01.027
-
van Zonneveld M, Honkoop P, Hansen BE, Niesters HG, Darwish Murad S, de Man RA, Schalm SW, Janssen HL, 2004: Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B[J]. Hepatology, 39, 804-810. doi: 10.1002/hep.20128
-
Wei XF, Gan CY, Cui J, Luo YY, Cai XF, Yuan Y, Shen J, Li ZY, Zhang WL, Long QX, Hu Y, Chen J, Tang N, Guo H, Huang AL, Hu JL, 2018: Identification of compounds targeting hepatitis B virus core protein dimerization through a split luciferase complementation assay[J]. Antimicrob Agents Chemother, 62, -.
-
Wu C, Zhang X, Tian Y, Song J, Yang D, Roggendorf M, Lu M, Chen X, 2010: Biological significance of amino acid substitutions in hepatitis B surface antigen (HBsAg) for glycosylation, secretion, antigenicity and immunogenicity of HBsAg and hepatitis B virus replication[J]. J Gen Virol, 91, 483-492. doi: 10.1099/vir.0.012740-0
-
Wu CY, Lin JT, Ho HJ, Su CW, Lee TY, Wang SY, Wu C, Wu JC, 2014: Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study[J]. Gastroenterology, 147, 143-151.e145. doi: 10.1053/j.gastro.2014.03.048
-
Wu C, Li B, Zhang X, Zhao K, Chen Y, Yuan Y, Liu Y, Chen R, Xu D, Chen X, Lu M, 2019: Complementation of wild-type and drug-resistant hepatitis B virus genomes to maintain viral replication and rescue virion production under Nucleos(t)ide analogs[J]. Virol Sin, 34, 377-385. doi: 10.1007/s12250-019-00143-y
-
Zhao K, Liu S, Chen Y, Yao Y, Zhou M, Yuan Y, Wang Y, Pei R, Chen J, Hu X, Zhou Y, Zhao H, Lu M, Wu C, Chen X, 2018: Upregulation of HBV transcription by sodium taurocholate cotransporting polypeptide at the postentry step is inhibited by the entry inhibitor Myrcludex B[J]. Emerg Microbes Infect, 7, 186-.
-
Zhou M, Huang Y, Cheng Z, Zhao F, Li J, Zhi X, Tian X, Sun W, Hu K, 2014: Revival, characterization, and hepatitis B virus infection of cryopreserved human fetal hepatocytes[J]. J Virol Methods, 207, 29-37. doi: 10.1016/j.jviromet.2014.06.015